{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T16:25:09Z","timestamp":1777047909444,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["amjmedsci.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.amjms.2022.10.004","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T02:35:50Z","timestamp":1670207750000},"page":"286-293","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["What lies in-between: C3 glomerulopathy with non-hemolytic renal microangiopathy and an ultra-rare C3 variant"],"prefix":"10.1016","volume":"365","author":[{"given":"Ali","family":"Jandal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weixiong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Gopal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Horner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leah","family":"Frater-Rubsam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjang","family":"Djamali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gauri","family":"Bhutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjms.2022.10.004_bib0001","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1681\/ASN.2015020184","article-title":"Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: An Etiologic Approach","volume":"26","author":"De Vriese","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjms.2022.10.004_bib0002","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjms.2022.10.004_bib0003","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ki.2012.63","article-title":"Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies","volume":"82","author":"Servais","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjms.2022.10.004_bib0004","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-220974","article-title":"Atypical haemolytic uremic syndrome (aHUS) and membranoproliferative glomerulonephritis (MPGN), different diseases or a spectrum of complement-mediated glomerular diseases?","volume":"2017","author":"Ankawi","year":"2017","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.amjms.2022.10.004_bib0005","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clinic J Am Soc Nephrol CJASN"},{"key":"10.1016\/j.amjms.2022.10.004_bib0006","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1681\/ASN.2015040385","article-title":"High-Throughput Genetic Testing for Thrombotic Microangiopathies and C3 Glomerulopathies","volume":"27","author":"Bu","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjms.2022.10.004_bib0007","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2022.10.004_bib0008","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.2215\/CJN.01820214","article-title":"Defining the Complement Biomarker Profile of C3 Glomerulopathy","volume":"9","author":"Zhang","year":"2014","journal-title":"Clinic J Am Soc Nephrol"},{"key":"10.1016\/j.amjms.2022.10.004_bib0009","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2215\/CJN.04700513","article-title":"C3 Glomerulopathy: Clinicopathologic Features and Predictors of Outcome","volume":"9","author":"Medjeral-Thomas","year":"2014","journal-title":"Clinic J Am Soc Nephrol"},{"key":"10.1016\/j.amjms.2022.10.004_bib0010","first-page":"2246","article-title":"Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature","volume":"28","author":"Manenti","year":"2013","journal-title":"Nephrol Dialy Transplant Offic Publ Eur Dialy Transpl Assoc Eur Renal Assoc"},{"key":"10.1016\/j.amjms.2022.10.004_bib0011","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/ckj\/sfs190","article-title":"Complement factor H mutation associated with membranoproliferative glomerulonephritis with transformation to atypical haemolytic uraemic syndrome","volume":"6","author":"Janssen van Doorn","year":"2013","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.amjms.2022.10.004_bib0012","first-page":"793","article-title":"Atypical hemolytic uremic syndrome with membranoproliferative glomerulonephritis","volume":"50","author":"Mehta","year":"2013","journal-title":"Indian Pediatr"},{"key":"10.1016\/j.amjms.2022.10.004_bib0013","first-page":"3811","article-title":"Three kidneys, two diseases, one antibody?","volume":"26","author":"Lorcy","year":"2011","journal-title":"Nephrol Dialy Transplant Offic Publ Eur Dialy Transpl Assoc Eur Renal Assoc"},{"key":"10.1016\/j.amjms.2022.10.004_bib0014","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12882-018-0952-z","article-title":"C3 glomerulonephritis and thrombotic microangiopathy of renal allograft after pulmonary infection in a male with concomitant two complement factor I gene variations: a case report","volume":"19","author":"Wen","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.amjms.2022.10.004_bib0015","unstructured":"NHLBI GO Exome Sequencing Project. Vol. 2021 (University of Washington)."},{"key":"10.1016\/j.amjms.2022.10.004_bib0016","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/imr.12500","article-title":"Complement component C3 - The \u201cSwiss Army Knife\u201d of innate immunity and host defense","volume":"274","author":"Ricklin","year":"2016","journal-title":"Immunol Rev"},{"key":"10.1016\/j.amjms.2022.10.004_bib0017","first-page":"584","article-title":"Thrombotic microangiopathy mimicking membranoproliferative glomerulonephritis","volume":"32","author":"Brackman","year":"2017","journal-title":"Nephrol Dialy Transplant Offic Publ Eur Dialy Transpl Assoc Eur Renal Assoc"},{"key":"10.1016\/j.amjms.2022.10.004_bib0018","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.4049\/jimmunol.1701695","article-title":"Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy","volume":"200","author":"Osborne","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.amjms.2022.10.004_bib0019","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.3389\/fimmu.2018.01813","article-title":"Analysis of C3 Gene Variants in Patients With Idiopathic Recurrent Spontaneous Pregnancy Loss","volume":"9","author":"Mohlin","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.amjms.2022.10.004_bib0020","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"10.1016\/j.amjms.2022.10.004_bib0021","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.4049\/jimmunol.1200679","article-title":"Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome","volume":"189","author":"Blanc","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.amjms.2022.10.004_bib0022","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1080\/07853890601097030","article-title":"Extended haplotypes in the complement factor H (CFH) and CFH-related (CFHR) family of genes protect against age-related macular degeneration: characterization, ethnic distribution and evolutionary implications","volume":"38","author":"Hageman","year":"2006","journal-title":"Ann Med"},{"key":"10.1016\/j.amjms.2022.10.004_bib0023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.0030041","article-title":"Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome","volume":"3","author":"Zipfel","year":"2007","journal-title":"PLoS Genet"},{"key":"10.1016\/j.amjms.2022.10.004_bib0024","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1055\/s-0034-1375299","article-title":"Treatment of C3 glomerulopathy with complement blockers","volume":"40","author":"Vivarelli","year":"2014","journal-title":"Semin Thrombos Hemos"},{"key":"10.1016\/j.amjms.2022.10.004_bib0025","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00467-015-3306-0","article-title":"Discontinuation of dialysis with eculizumab therapy in a pediatric patient with dense deposit disease","volume":"31","author":"Tran","year":"2016","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"key":"10.1016\/j.amjms.2022.10.004_bib0026","doi-asserted-by":"crossref","first-page":"748","DOI":"10.2215\/CJN.12901211","article-title":"Eculizumab for dense deposit disease and C3 glomerulonephritis","volume":"7","author":"Bomback","year":"2012","journal-title":"Clinic J Am Soc Nephrol CJASN"},{"key":"10.1016\/j.amjms.2022.10.004_bib0027","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1053\/j.ajkd.2014.09.025","article-title":"Eculizumab for treatment of rapidly progressive C3 glomerulopathy","volume":"65","author":"Le Quintrec","year":"2015","journal-title":"Am J Kidney Dis"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962922004311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962922004311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:42:36Z","timestamp":1757702556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962922004311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0002962922004311"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2022.10.004","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What lies in-between: C3 glomerulopathy with non-hemolytic renal microangiopathy and an ultra-rare C3 variant","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2022.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc. on behalf of Southern Society for Clinical Investigation.","name":"copyright","label":"Copyright"}]}}